Targeted inhibition of heat shock protein 90 suppresses tumor necrosis factor-α and ameliorates murine intestinal inflammation

Inflammatory Bowel Diseases

Volumn 20, Issue 4, 2014, Pages 685-694

  Collins, Colm B ^a   Strassheim, Derek ^a   Aherne, Carol M ^b   Yeckes, Alyson R ^a   Jedlicka, Paul ^b   De Zoeten, Edwin F ^a  

^a University of Colorado Denver and Children s Hospital Colorado   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Colitis; Heat shock protein 90

Indexed keywords

ADENOSINE TRIPHOSPHATASE; CD45RB ANTIGEN; DEXTRAN SULFATE; GAMMA INTERFERON; HEAT SHOCK PROTEIN 90; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; LUCIFERASE; NOVOBIOCIN; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; ENZYME INHIBITOR; TRANSCRIPTION FACTOR RELA;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; ILEITIS; IN VITRO STUDY; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CD4+ T LYMPHOCYTE; CELL NUCLEUS; CELL PROLIFERATION; CHEMICALLY INDUCED; CHEMISTRY; DRUG EFFECTS; ENZYME ACTIVATION; GENETICS; IMMUNOLOGY; INTESTINE MUCOSA; JURKAT CELL LINE; METABOLISM; PATHOLOGY;

ADENOSINE TRIPHOSPHATASES; ADOPTIVE TRANSFER; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL NUCLEUS; CELL PROLIFERATION; COLITIS; CYTOKINES; DEXTRAN SULFATE; ENZYME ACTIVATION; ENZYME INHIBITORS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; ILEITIS; INTESTINAL MUCOSA; JURKAT CELLS; MICE; MICE, INBRED C57BL; NOVOBIOCIN; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84898728693     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/01.MIB.0000442839.28664.75     Document Type: Article

References (37)

1. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46-54 e42; quiz e30.
2. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60:780-787.
3. Otaka M, Odashima M, Watanabe S. Role of heat shock proteins (molecular chaperones) in intestinal mucosal protection. Biochem Biophys Res Commun. 2006;348:1-5.
4. Collins CB, Aherne CM, Yeckes A, et al. Inhibition of N-terminal ATPase on HSP90 attenuates colitis through enhanced Treg function. Mucosal Immunol. 2013.
5. Prakken BJ, Wendling U, van der Zee R, et al. Induction of IL-10 and inhibition of experimental arthritis are specific features of microbial heat shock proteins that are absent for other evolutionarily conserved immunodominant proteins. J Immunol. 2001;167:4147-4153.
6. Dello Russo C, Polak PE, Mercado PR, et al. The heat-shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin suppresses glial inflammatory responses and ameliorates experimental autoimmune encephalomyelitis. J Neurochem. 2006;99:1351-1362.
7. Chatterjee A, Dimitropoulou C, Drakopanayiotakis F, et al. Heat shock protein 90 inhibitors prolong survival, attenuate inflammation, and reduce lung injury in murine sepsis. Am J Respir Crit Care Med. 2007;176:667-675.
8. Poulaki V, Iliaki E, Mitsiades N, et al. Inhibition of Hsp90 attenuates inflammation in endotoxin-induced uveitis. FASEB J. 2007;21:2113-2123.
9. de Zoeten EF, Wang L, Butler K, et al. Histone deacetylase 6 and heat shock protein 90 control the functions of foxp3+ T-regulatory cells. Mol Cell Biol. 2011;31:2066-2078.
10. Marcu MG, Chadli A, Bouhouche I, et al. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATPbinding domain in the carboxyl terminus of the chaperone. J Biol Chem. 2000;275:37181-37186.
11. Pratt WB, Toft DO. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood). 2003;228:111-133.
12. Xie Y, Cahill CM, Asea A, et al. Heat shock proteins and regulation of cytokine expression. Infect Dis Obstet Gynecol. 1999;7:26-30.
13. De AK, Kodys KM, Yeh BS, et al. Exaggerated human monocyte IL-10 concomitant to minimal TNF-alpha induction by heat-shock protein 27 (Hsp27) suggests Hsp27 is primarily an antiinflammatory stimulus. J Immunol. 2000;165:3951-3958.
14. Xie Y, Chen C, Stevenson MA, et al. Heat shock factor 1 represses transcription of the IL-1beta gene through physical interaction with the nuclear factor of interleukin 6. J Biol Chem. 2002;277:11802-11810.
15. Wang X, Ju W, Renouard J, et al. 17-allylamino-17-demethoxygeldanamycin synergistically potentiates tumor necrosis factor-induced lung cancer cell death by blocking the nuclear factor-kappaB pathway. Cancer Res. 2006;66:1089-1095.
16. Kontoyiannis D, Pasparakis M, Pizarro TT, et al. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity. 1999;10:387-398.
17. Smith P, Mangan NE, Walsh CM, et al. Infection with a helminth parasite prevents experimental colitis via a macrophage-mediated mechanism. J Immunol. 2007;178:4557-4566.
18. Collins CB, Aherne CM, Kominsky D, et al. Retinoic acid attenuates ileitis by restoring the balance between T-helper 17 and T regulatory cells. Gastroenterology. 2011;141:1821-1831.
19. Collins CB, Ho J, Wilson TE, et al. CD44 deficiency attenuates chronic murine ileitis. Gastroenterology. 2008;135:1993-2002.
20. Melgar S, Karlsson L, Rehnstrom E, et al. Validation of murine dextran sulfate sodium-induced colitis using four therapeutic agents for human inflammatory bowel disease. Int Immunopharmacol. 2008;8:836-844.
21. Kim TW, Seo JN, Suh YH, et al. Involvement of lymphocytes in dextran sulfate sodium-induced experimental colitis. World J Gastroenterol. 2006; 12:302-305.
22. Molitor JA, Walker WH, Doerre S, et al. NF-kappa B: a family of inducible and differentially expressed enhancer-binding proteins in human T cells. Proc Natl Acad Sci U S A. 1990;87:10028-10032.
23. Geng J, Xiao S, Zheng Z, et al. Gambogic acid protects from endotoxin shock by suppressing pro-inflammatory factors in vivo and in vitro. Inflamm Res. 2013;62:165-172.
24. Odashima M, Otaka M, Jin M, et al. Zinc L-carnosine protects colonic mucosal injury through induction of heat shock protein 72 and suppression of NF-kappaB activation. Life Sci. 2006;79:2245-2250.
25. Li X, Luo R, Jiang R, et al. The role of the Hsp90/Akt pathway in myocardial calpain-induced caspase-3 activation and apoptosis during sepsis. BMC Cardiovasc Disord. 2013;13:8.
26. Burress GC, Musch MW, Jurivich DA, et al. Effects of mesalamine on the hsp72 stress response in rat IEC-18 intestinal epithelial cells. Gastroenterology. 1997;113:1474-1479.
27. Thiara AS, Cundliffe E. Cloning and characterization of a DNA gyrase B gene from Streptomyces sphaeroides that confers resistance to novobiocin. EMBO J. 1988;7:2255-2259.
28. Rath HC, Schultz M, Freitag R, et al. Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect Immun. 2001;69:2277-2285.
29. Aranda R, Sydora BC, McAllister PL, et al. Analysis of intestinal lymphocytes in mouse colitis mediated by transfer of CD4+, CD45RBhigh T cells to SCID recipients. J Immunol. 1997;158:3464-3473.
30. Ayres JS, Trinidad NJ, Vance RE. Lethal inflammasome activation by a multidrug-resistant pathobiont upon antibiotic disruption of the microbiota. Nat Med. 2012;18:799-806.
31. Ruiz PA, Braune A, Holzlwimmer G, et al. Quercetin inhibits TNFinduced NF-kappaB transcription factor recruitment to proinflammatory gene promoters in murine intestinal epithelial cells. J Nutr. 2007;137: 1208-1215.
32. Kronman MP, Gerber JS, Prasad PA, et al. Variation in antibiotic use for children hospitalized with inflammatory bowel disease exacerbation: a multicenter validation study. J Pediatric Infect Dis Soc. 2012;1: 306-313.
33. Khan KJ, Ullman TA, Ford AC, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011;106:661-673.
34. Gionchetti P, Rizzello F, Lammers KM, et al. Antimicrobials in the management of inflammatory bowel disease. Digestion. 2006;73(suppl 1):77-85.
35. Eder JP, Wheeler CA, Teicher BA, et al. A phase I clinical trial of novobiocin, a modulator of alkylating agent cytotoxicity. Cancer Res. 1991;51:510-513.
36. Kennedy MJ, Armstrong DK, Huelskamp AM, et al. Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer. J Clin Oncol. 1995;13:1136-1143.
37. Limson BM, Romansky MJ. Novobiocin, a new antibiotic; laboratory and clinical evaluation of thirty patients with bacterial pneumonia. Antibiotic Med Clin Ther. 1956;2:277-281.